New hope for rare paralysis: drug combo targets toxic cholesterol byproducts
NCT ID NCT02314208
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This study tested three drugs (Xenbilox, Tahor, and Resveratrol) in 12 adults with a rare inherited form of spastic paraplegia called SPG5. The goal was to lower levels of harmful oxysterols, which are toxic byproducts of cholesterol that damage nerve cells. Each participant took the drugs in turn for two months, and the researchers measured changes in blood oxysterol levels. The approach aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPASTIC PARAPLEGIA, HEREDITARY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pitié-Salpêtrière Hospital
Paris, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.